Sign In
Buy HRTX
$0.447
-0.0032 (-0.711%)
At Close: Jun 03, 2026
Heron Therapeutics (NASDAQ:HRTX) & Enliven Therapeutics (NASDAQ:ELVN) Head to Head Contrast
01:34am, Thursday, 05'th Feb 2026
Heron Therapeutics (NASDAQ: HRTX - Get Free Report) and Enliven Therapeutics (NASDAQ: ELVN - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare
CARY, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced preliminary, unaudit
Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Average Recommendation of “Hold” from Analysts
05:12am, Wednesday, 24'th Dec 2025
Heron Therapeutics, Inc. (NASDAQ: HRTX - Get Free Report) has been assigned a consensus rating of "Hold" from the five brokerages that are currently covering the company, MarketBeat Ratings reports. O
Congress Park Capital LLC Acquires 621,908 Shares of Heron Therapeutics, Inc. $HRTX
04:44am, Thursday, 18'th Dec 2025
Congress Park Capital LLC lifted its holdings in shares of Heron Therapeutics, Inc. (NASDAQ: HRTX) by 27.4% during the undefined quarter, according to the company in its most recent 13F filing with th
CARY, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced the inclusion of APO
Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives $4.50 Average Price Target from Brokerages
02:14am, Tuesday, 02'nd Dec 2025
Heron Therapeutics, Inc. (NASDAQ: HRTX - Get Free Report) has been given an average rating of "Hold" by the five analysts that are covering the stock, MarketBeat reports. One analyst has rated the sto
Heron Therapeutics, Inc. (HRTX) Q3 2025 Earnings Call Transcript
03:26pm, Tuesday, 04'th Nov 2025
Heron Therapeutics, Inc. ( HRTX ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Melissa Jarel - Executive Director of Legal Craig Collard - CEO & Director Mark Hensley - Exec
Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
10:30am, Tuesday, 04'th Nov 2025
Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare wi
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates
10:15am, Tuesday, 04'th Nov 2025
Heron Therapeutics (HRTX) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.03 per share a year ago.
Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress
08:00am, Tuesday, 04'th Nov 2025
Generated Q3 2025 Net Revenue of $38.2 million and year-to-date revenue of $114.3 million; reaffirmed 2025 Net Revenue Guidance of $153 million - $163 million and adjusted EBITDA of $9.0 - $13.0 milli
Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors
05:58pm, Wednesday, 29'th Oct 2025
CARY, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced the appointment of T
Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
04:20pm, Tuesday, 21'st Oct 2025
CARY, N.C., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company wil
Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value
07:45am, Friday, 15'th Aug 2025
CARY, N.C. , Aug. 15, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that its Board of Directors (th
Heron Therapeutics, Inc. (HRTX) Q2 2025 Earnings Call Transcript
03:46pm, Friday, 08'th Aug 2025
Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q2 2025 Earnings Conference Call August 8, 2025 8:30 AM ET Company Participants Craig Alexander Collard - CEO & Director Ira Duarte - Executive VP & CFO Mark E.
Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
10:30am, Friday, 08'th Aug 2025
Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wa
